Off Label Use of Suboxone for Treatment Resistant Depression

George Kamajian, Robert Cable, Jonathan Greco, Brady Laughlin and Tanya deGroot



Major Depressive Disorder (MDD) is a condition that affects approximately 12% of the population [1] and recurs at a rate between 50-85% regardless of treatment [2]. Treatment resistant depression (TRD) is considered if patients
do not show alleviation of depressive symptoms after at least two trials of antidepressants from different pharmacologic classes [3]. Current antidepressant therapies which modulate serotonin, norepinephrine, and dopamine are based on the monoamine hypothesis, but the mechanism of MDD is now known to be more complex [4]. More aggressive treatment options including ketamine infusions, deep brain stimulation, and magnetic seizure therapy [5, 6] have also been applied in attempts to influence the unknown areas of our understanding of depression.

Published on: May 4, 2016
doi: 10.17756/jrdsas.2016-021
Citation: Kamajian G, Cable R, Greco J, Laughlin B, deGroot T. 2016. Off Label Use of Suboxone for Treatment Resistant Depression. J Reward Defic Syndr Addict Sci 2(1): 1-2.